

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

Complete if Known

P E INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

Application Number	10/821,745
Filing Date	04/09/2004
First Named Inventor	Snyder
Art Unit	1615
Examiner Name	To be assigned
Attorney Docket Number	1030.004

## U. S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
		US- 4,853,224	08/01/1989	Wong	
		US- 5,273,751	12/28/1993	Dubroff	
		US- 5,375,611	12/27/1994	Lindqvist et al.	
		US- 5,401,880	03/28/1995	Clark et al.	
		US- 5,554,187	09/10/1996	Rizzo III	
		US- 5,569,463	10/29/1996	Helmus et al.	
		US- 5,616,122	04/01/1997	Lam et al.	
		US- 5,624,704	04/29/1997	Darouiche et al.	
		US- 5,743,274	04/28/1998	Peyman	
		US- 5,843,184	12/01/1998	Cionni	
		US- 5,843,186	12/1/1998	Christ	
		US- 5,876,438	03/02/1999	Kelleher et al.	
		US- 5,902,283	05/11/1999	Darouiche et al.	
		US- 5,980,928	11/9/1999	Terry	
		US- 6,162,487	12/19/2000	Darouiche	
		US- 6,322,592	11/27/2001	Lucas et al.	
		US- 6,352,542	03/05/2002	Snyder	
		US-			

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		WO 00/62760	10/26/2000	Cohan et al.		
		WO 01/32140	05/10/2001	Darougar et al.		
		WO 02/100318	12/19/2002	Varner et al.		
		EP 0544948 A1	06/09/1993	University of Miami		
		WO 03/061625	07/31/2003	Snyder et al.		

Examiner Signature		Date Considered
--------------------	--	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /I.G./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

MAR 11 2005

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

*(Use as many sheets as necessary)*

## Shee

1

10

1

**Complete if Known**

Application Number	10/821,745
Filing Date	04/09/2004
First Named Inventor	Snyder
Art Unit	1615
Examiner Name	To be assigned
Attorney Docket Number	1030.004

## U. S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
		KR 2001-018344A	03/2001	Choi et al. (abst. only)		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. (I.G.)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(use as many sheets as necessary)</small>		Application Number	10/821,745
Sheet	1	Filing Date	4/9/2004
of 0		First Named Inventor	Snyder
		Group Art Unit	
		Examiner Name	
		Attorney Docket Number	1030-004

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
		Pandey et al., Intracapsular ring sustained 5-fluorouracil delivery system for the prevention of posterior capsule opacification in rabbits: a histological study, J CATARACT REFRACT SURG 2002 Jan. 28 (1): 139-48.
		Shi W et al., Prolongation of corneal allograft survival in mice with a cyclosporine drug delivery system implant, CHUNG HUA YEN KO TSA CHIH 2002 Aug. 38 (8): 502-5.
		Mantripragada, S., A lipid based depot (DepoFoam technology) for sustained release drug delivery, PROG LIPID RES 2002 Sep. 41 (5) 392-406.
		Das et al., Effect of vancomycin on Staphylococcus epidermidis adherence to poly(methyl methacrylate) intraocular lenses, J CATARACT REFRACT SURG 2002 Apr. 28 (4): 703-8.
		Cheng et al., Treatment or prevention of herpes simplex virus retinitis with intravitreally injectable crystalline 1-O-hexadecylpropanediol-3-phospho-ganciclovir, INVEST OPHTHALMOL VIC SCI 2002 Feb; 43 (2): 515-21.
		Herrero-Vanrell et al., Biodegradable microspheres for vitreoretinal drug delivery, ADV DRUG DELIV REV 2001 Oct 31; 52 (1): 5-16
		Herrero-Vanrell et al., Biodegradable PLGA microspheres loaded with ganciclovir for intraocular administration. Encapsulation technique, in vitro release profiles, and sterilization process, PHARM RES 2000 Oct; 17 (10): 1323-8
		Jaffe et al., Fluocinolone acetonide sustained drug delivery device to treat severe uveitis, OPHTHALMOLOGY 2000 Nov; 107 (11): 2024-33
		Jaffe et al., Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device, INVEST OPHTHALMOL VIS SCI 2000 Oct; 41 (11); 3569-75
		Kunou et al., Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis, J CONTROL RELEASE 2000 Aug 10; 68(2): 263-71
		Einmahl et al., Concomitant and controlled release of dexamethasone and 5-fluorouracil from poly(ortho ester), INT J PHARM 1999 Aug 20; 185(2): 189-98

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED -- EXCEPT THOSE LISTED ON A SEPARATE SHEET. /L.G./

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

## Complete if Known

Application Number	10/821,745
Filing Date	4/9/2004
First Named Inventor	Snyder
Group Art Unit	
Examiner Name	

Sheet 1 of 0

Attorney Docket Number 1030-004

## OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Tetz et al., Inhibition of posterior capsule opacification by an intraocular-lens-bound sustained drug delivery system: an experimental animal study and literature review, J CATARACT REFRACT SURG 1996 Oct; 22 (8): 1070-9	
		Rabowsky et al., The use of bioerodible polymers and daunorubicin in glaucoma filtration surgery, OPHTHALMOLOGY 1996 May; 103 (5): 800-7	
		Nishi et al., Effect of intraocular sustained release of indomethacin on postoperative inflammation and posterior capsule opacification, J CATARACT REFRACT SURG 1996; 22 Supp. 1: 806-10	
		Chetoni et al., Ocular mini-tablets for controlled release of timolol: evaluation in rabbits, J OCUL PHARMACOL THER 1996 Fall; 12 (3): 245-52	
		Kiremitci-Gumusderelioglu et al., A novel MMC-loaded pHEMA drainage device for the treatment of glaucoma: in vitro and in vivo studies, J BIOMATER SCI POLYM ED 1996; 7 (1): 857-69	
		Borhani et al., Suppression of experimental proliferative vitreoretinopathy by sustained intraocular delivery of 5-FU, INT OPHTHALMOL 1995; 19 (1): 43-9	
		Joshi A., Microparticulates for ophthalmic drug delivery, J OCUL PHARMACOL 1994 Spring; 10(1): 29-45	
		Rahimy et al., Polysulfone capillary fiber for intraocular drug delivery: in vitro and in vivo evaluations, J DRUG TARGET 1994; 2 (4): 289-98	
		Chang DF et al., Two Clinical trials of an intraocular steroid delivery system for cataract surgery, TRANS AM OPHTHALMOL SOC. 1999; 97: 261-74; discussion 274-9.	
		DuBosar, Ryan, Intraocular steroid delivery system completes FDA phase 2 trial; New drug delivery system could make postop cataract management easier and more efficient, OCULAR SURGERY NEWS, a SLACK Incorporated newspaper, November 1, 1997.	
		Chang, David F., An Intraocular Steroid Delivery System for Cataract Surgery, BRITISH JOURNAL OF OPHTHALMOLOGY, March 9, 2001.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

ALL REFERENCES CONSIDERED EXCEPT WHERE REPLIED THROUGH /L.G./